Doubling the Iron Dose to Prevent IDA in Twin Pregnant Women
Condition: Hematologic Pregnancy Complications
MeSH terms: Pregnancy Complications; Pregnancy Complications, Hematologic
Study type: Interventional
Phase: Phase 4

Summary: 
      In twin pregnancies, the maternal iron demands are magnified, estimated at 1.8 times more
      than in singleton pregnancies due to greater maternal red blood cell mass and plasma volume
      expansion as well as increased fetal and placental requirements.

      With a lack of randomized controlled trials assessing the adequacy of iron supplements on
      twin pregnancy, various recommendations are based on level 3 clinical expert opinions at
      most.
    

Detailed description: 
      Iron deficiency anemia (IDA) is a very prevalent condition in pregnancy, affecting nearly 18%
      of all pregnant women during all three trimesters, with as many as 29%of women affected
      during the third trimester.

      In twin pregnancies, the maternal iron demands are magnified, estimated at 1.8 times more
      than in singleton pregnancies due to greater maternal red blood cell mass and plasma volume
      expansion as well as increased fetal and placental requirements. Thus, maternal hemoglobin
      (Hgb) in multiple pregnancies is lower in all trimesters compared with singleton gestations,
      with a rate of IDA estimated to be 2.4 to even 4 times higher.

      Expert opinion relying on the increased risk for micronutrient deficiency in twin pregnancies
      recommends supplementation of iron beyond that contained in a typical prenatal vitamin.
      Moreover, some experts support doubling the dose of multivitamins containing 30 mg of
      elemental iron during the second and third trimesters of a twin pregnancy, regardless of
      maternal Hgb and ferritin concentrations.

      With a lack of randomized controlled trials assessing the adequacy of iron supplements on
      twin pregnancy, various recommendations are based on level 3 clinical expert opinions at
      most. The purpose of our study was to assess the efficacy of a single versus a double daily
      iron supplement dose in iron deficient women with twin pregnancies. Determining the effect of
      this intervention on maternal iron stores and immediate neonatal outcome measures will assist
      in defining evidence based recommendations for prenatal care.
    

Intervention name(s): Feroglobin single daily use; Feroglobin twice daily dose
Intervention type(s): Drug; Drug
Intervention description(s): Feroglobin single daily use ( IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.; Feroglobin twice daily dose ( IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
Other intervention name(s): IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE; 'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE
Intervention MeSH terms: Iron
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Prevention
Keywords: Pregnancy, Twins , Iron Deficiency Anaemia